Regeneron begins COVID-19 antibody cocktail late-stage trial, shares rise

FAN Editor

(Reuters) – Regeneron Pharmaceuticals Inc said on Monday it began late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19, sending its shares up nearly 4%.

Continue Reading Below

The trial, run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), would test REGN-COV2’s ability to prevent infection in those who have had close exposure to a COVID-19 patient.

REGN-COV2, an experimental therapy, has also entered into mid-to-late stage phase of two trials testing its effectiveness in hospitalized and non-hospitalized COVID-19 patients, Regeneron said.

WHAT IS REGENERON?

Regeneron is among the few front-runners who have begun human trials testing their experimental therapies to fight COVID-19, including Gilead Sciences, Eli Lilly and AbbVie.

Ticker Security Last Change Change %
REGN REGENERON PHARMACEUTICALS INC. 622.45 +13.28 +2.18%

Regeneron in June began human trial of the antibody cocktail as a treatment for COVID-19, with an “adaptive” design to quickly move to include thousands of patients.

The late-stage trial will be conducted across 100 sites and expected to enroll 2,000 patients in the U.S. It follows a safety assessment of the cocktail in an early-stage trial by an independent committee.

CASINO EXEC DIES IN JULY 4 WATERCRAFT ACCIDENT

Antibodies are proteins made by the body’s immune system that recognize, bind and neutralize an invading virus.

Dr. Len Schleifer is CEO of Regeneron. (Credit: Regeneron)

Regeneron’s cocktail – a combination of an antibody made by the company and a second antibody isolated from recovered COVID-19 patients – is designed to bind the antibodies to the coronavirus’ spike protein.

The drugmaker was also testing its rheumatoid arthritis drug, Kevzara, with Sanofi to treat COVID-19, which on Thursday failed to meet the main goal of a U.S. study testing it in the most critically ill COVID-19 patients.

Shares of the drugmaker were up 3.6% at $645 in trading before the bell.

(Reporting by Saumya Sibi Joseph and Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Free America Network Articles

Leave a Reply

Next Post

Coronavirus updates: Scientists call on WHO to recognize airborne threat; India's cases surpass Russia's

52 Min Ago WHO must fully recognize the risk of airborne virus, scientists say A group of 239 scientists from around the world is reportedly set to push for the World Health Organization to give greater acknowledgment to the risk of the airborne spread of the coronavirus. The experts are […]